Background: Colorectal cancer is one of the most prevalent forms of cancer and is associated with a high mortality rate. Additionally, an increasing number of adults under 50 are being diagnosed with the disease. This underscores the importance of leveraging modern technologies, such as artificial intelligence, for early diagnosis and treatment support. Methods: Eight classifiers were utilized in this research: Random Forest, XGBoost, CatBoost, LightGBM, Gradient Boosting, Extra Trees, the k-nearest neighbor algorithm (KNN), and decision trees. These algorithms were optimized using the frameworks Optuna, RayTune, and HyperOpt. This study was conducted on a public dataset from Brazil, containing information on tens of thousands of patients. Results: The models developed in this study demonstrated high classification accuracy in predicting one-, three-, and five-year survival, as well as overall mortality and cancer-specific mortality. The CatBoost, LightGBM, Gradient Boosting, and Random Forest classifiers delivered the best performance, achieving an accuracy of approximately 80% across all the evaluated tasks. Conclusions: This research enabled the development of effective classification models that can be applied in clinical practice.
Introduction: Both BRAF V600E mutation and mismatch repair deficiency bear prognostic and predictive relevance in metastatic colorectal cancer, yet impact of simultaneous occurrence of both factors on prognosis is under-investigated. Aim: Although retrospective studies support localised therapies for oligometastatic CRC in the general population, data for tumours harbouring both alterations are scarce. Case study: In 2013, a 66-year-old female underwent radical resection for pT3 N0 distal sigmoid adenocarcinoma. Five months later she was diagnosed with oligometastatic recurrence in the right ovary. In 2014 the woman underwent hysterectomy and bilateral adnexectomy. Histopathology of the resected material confirmed adenocarcinoma metastasis in the right ovary. As the radicality of the resection was uncertain, the patient received 12 cycles of FOLFIRI chemotherapy after which the treatment was suspended due to no evidence of the disease. The follow-up imaging showed no signs of recurrence. A retrospective testing of tumor samples from metastasectomy revealed a BRAF V600E mutation and loss of MLH1, PMS2 expression indicating dMMR. Results and discussion: Recently emerging data indicate at better prognosis in metastatic colorectal cancer with coexisting BRAF V600E mutation and dMMR as compared to cases with either of these biomarkers. The literature on the outcomes of metastatic resection in population with both alterations is scarce. The patient described here is an example of favourable outcome, with over 10-year survival after local treatment of colorectal metastases with aforementioned molecular profile. Conclusions: Metastasis resection, should be further investigated in colorectal cancers harbouring high risk molecular alterations.
Introduction: Dry eye disease (DED) is a prevalent and debilitating ocular condition characterized by discomfort, visual disturbances, and tear film instability. Recent therapeutic developments have introduced perfluorohexyloctane ophthalmic solution (Miebo®) as a potential treatment for DED, particularly in patients with meibomian gland dysfunction (MGD). Aim of the Study: This narrative review aims to evaluate the efficacy and safety of Miebo® in treating DED based on current clinical evidence. Materials and Methods: A comprehensive literature search was conducted in PubMed, Embase, and Cochrane Library databases up to May 2024 resulting in the identification of 9 studies. The review included randomized controlled trials, prospective cohort studies, and systematic reviews that focused on the use of Miebo® for DED. Data on efficacy in improving tear film stability and symptom relief, as well as safety profiles, were extracted and analyzed. Results: The evidence indicates that Miebo® significantly enhances tear film stability and alleviates symptoms of DED, with pronounced benefits observed in patients with MGD. Comparative studies demonstrate that Miebo® is more effective than conventional treatments, such as artificial tears and lipid-based formulations. Safety assessments reveal minimal ocular surface discomfort and no significant systemic adverse events associated with Miebo® use. Conclusion: Miebo® shows substantial efficacy and a favorable safety profile in managing DED, making it a valuable therapeutic option, particularly for patients who do not respond to traditional therapies. However, further research is needed to confirm its long-term effectiveness and safety.
Introduction: Myxoedema coma is a severe and rare manifestation of hypothyroidism that requires immediate and effective intervention. Traditional treatment involves the use of levothyroxine, a synthetic thyroid hormone. Liquid levothyroxine presents an alternative formulation that may offer advantages in the critical care setting, particularly when gastrointestinal absorption is impaired. Aim of the Study: This narrative review aims to evaluate the efficacy and application of liquid levothyroxine in the treatment of myxoedema coma, comparing it to other available forms and providing insights into its clinical use. Materials and Methods: A comprehensive literature search was conducted using databases such as PubMed, Medline, and Cochrane Library. Studies, clinical trials, case reports, and reviews were included if they addressed the use of liquid levothyroxine in myxoedema coma. Data were extracted and analyzed to assess the pharmacokinetics, administration protocols, outcomes, and comparative efficacy of liquid levothyroxine. Results: The review identified several key studies and case reports indicating that liquid levothyroxine offers superior bioavailability and faster onset of action compared to oral tablets, particularly in patients with compromised gastrointestinal function. Case studies demonstrated improved clinical outcomes and recovery times with liquid levothyroxine, highlighting its potential benefits in the acute management of myxoedema coma. Conclusion: Liquid levothyroxine appears to be a promising alternative for the treatment of myxoedema coma, offering enhanced absorption and rapid therapeutic effects. While preliminary data are encouraging, further research and clinical trials are necessary to establish standardized treatment protocols and confirm its efficacy. Understanding the role of liquid levothyroxine in this critical condition can enhance treatment strategies and improve patient outcomes.
Introduction: Parkinson’s disease (PD) is a fast-growing neurodegenerative condition caused by the deficiency of dopamine (Bloem et al., 2021). Main symptoms include tremor, bradykinesia, muscular rigidity and postural instability (Ye et al., 2023). Although PD treatment primarily involves pharmacotherapy, physical activity-based treatments such as tango dance can improve the quality of life of patients. Aim of the study: This narrative review aims to assess the impact of the therapeutic benefits of tango dance therapy for people with PD. Materials and methods: A comprehensive literature search was conducted in the PubMed database up to 2024. The review included randomised controlled trials, case reports, and pilot studies focused on the impact of tango on PD. Results: Several studies have evaluated the impact of tango on patients with PD. Some of them found that tango improves dynamic balance and walking, reduces the risk of falling, improves body awareness, stability, and emotional well-being among patients with PD. Conclusions: The impact of tango on PD is not yet conclusively documented, and further research is needed.